Just a few years ago, sequencing the human genome was a three billion dollar project. Today, that information is being sold to consumers for only a few hundred dollars. It gives individuals more knowledge about their risk for diseases, such as cancer or Alzheimer's. But do consumers or even family physicians understand the science enough to make sound decisions from this type of test? And what will others, including insurance companies, do with the information? It raises lots of medical and ethical questions which we'll explore Wednesday morning at 9 as host Dan Moulthrop leads a discussion on the brave new world of direct-to-consumer and clinical genetic testing.